| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.9 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |